Heidi Anne Duerr, MPH

Extreme risk protection orders may be an effective suicide prevention tool.

How can Ibogaine help patients with Alcohol Use Disorder, specifically in veterans?

What effects do lifestyle factors have on brain aging and neuropsychiatic symptoms?

Data presented at ACNP meeting demonstrated safety, tolerability, and efficacy for SPN-820 for MDD.

A poster at the ACNP Annual Meeting utilized a novel risk-informed case-control design to improve biomarker differentiation for ADHD.

Machine learning may help science better understand cognitive impairment in schizophrenia and improve prevention and patient care.

Thomas R. Kosten, MD, shares thoughts on the latest schizophrenia genetic model research presented at the meeting.

New research links reduced synaptic density,early psychosis, and cannabis use, offering insights into negative symptoms and potential interventions.

Stephanie Gorka, PhD, shared findings at the ACNP Annual Meeting on orexin receptor agonists addressing AUDs.

In highlighting recent advances and fostering collaboration and networking, the ACNP Annual Meeting helps usher in 2025 with hope and positivity.

Thomas R. Kosten, MD, shares insights on the ACNP meeting along with his excitement for potential new treatments.

NIH directors discuss initiatives, advances, and more at the annual meeting.

Previewing the 63rd ACNP Annual Meeting, which is set to highlight the latest research in psychiatry.

It's time to better support clinicians prescribing clozapine, Peter J. Weiden, MD, shared in an interview.

What does the clozapine REMS recommendations from the FDA Advisory Committees mean for clinical care?

Gordon Lavigne, MEd, CEO of the Schizophrenia & Psychosis Action Alliance, talk about the joint FDA committee's vote on clozapine REMS.

Calling it a barrier to care, FDA committees decide to end clozapine REMS.

Although safety and tolerability was positive, ALTO-100 failed to reach primary endpoint in MDD study.

Jelena Kunovac, MD, MS, discusses last week's approval of Cobenfy, an agent with a novel mechanism of action that could revolutionize schizophrenia treatment.

The US Food and Drug Administration approves Cobenfy (KarXT), the first new agent with a novel mechanism of action for schizophrenia more than 50 years.

Why are experts excited about KarXT, a novel muscarinic acetylcholine receptor agonist that, if approved, is poised to revolutionize schizophrenia treatment?

John Krystal, MD, explores the future of ketamine and psychedelics in psychiatry, shedding light on their potential to improve patient care by increasing options treatment options.

The PDUFA date for KarXT for schizophrenia is September 26, 2024. Here’s what one expert thinks of this potential treatment.

The FDA instead issued a CRL for MDMA-assisted psychotherapy for PTSD, requesting an additional phase 3 trial to examine safety and efficacy. Other psychedelic compounds are proceeding with trials for psychiatric conditions. Learn more here.

Prepare your patients for the Fourth of July with expert tips from Roger Rivera, FNP, PMHNP, DNP, on managing risky behaviors, adherence distractions, PTSD-related triggers, and sensory overload during the holiday.

June held negative news for psychedelics and an accepted sNDA for brexpiprazole + sertraline for adults with PTSD.

Judith Joseph, MD, MBA, shares her journey of balancing clinical work with social media mental health advocacy.